Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

NCT00663429 is registered in ClinicalTrials.gov with Callisto Pharmaceuticals as lead sponsor.

NCT NCT00663429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00663429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Extension Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Lead sponsor
Callisto Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2007
Completion date
March 31, 2010
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma